	US 12,213,952 B1
	Biologic enhancement formulation
Stephen J. Harkins, Tucson, AZ (US); and Mitchell R. Halter, Tucson, AZ (US)
Assigned to HEH RESEARCH & DEVELOPMENT SERVICES, INC., Tucson, AZ (US)
Filed by HEH RESEARCH & DEVELOPMENT SERVICES, INC., Tucson, AZ (US)
Filed on Jan. 12, 2024, as Appl. No. 18/412,174.
Application 18/412,174 is a continuation in part of application No. 17/244,814, filed on Apr. 29, 2021, granted, now 11,931,323.
Application 17/244,814 is a continuation in part of application No. PCT/US2019/062257, filed on Nov. 19, 2019.
Application PCT/US2019/062257 is a continuation of application No. 16/195,425, filed on Nov. 19, 2018, abandoned.
Application 16/195,425 is a continuation in part of application No. 15/913,619, filed on Mar. 6, 2018, abandoned.
Claims priority of provisional application 62/469,376, filed on Mar. 9, 2017.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/00 (2006.01); A23L 2/56 (2006.01); A23L 2/60 (2006.01); A23L 33/155 (2016.01); A61K 9/00 (2006.01); A61K 31/122 (2006.01); A61K 31/401 (2006.01); A61K 31/706 (2006.01); A61K 31/7068 (2006.01)

CPC A61K 31/122 (2013.01) [A23L 2/56 (2013.01); A23L 2/60 (2013.01); A23L 33/155 (2016.08); A61K 9/0095 (2013.01); A61K 31/401 (2013.01); A61K 31/706 (2013.01); A61K 31/7068 (2013.01); A23V 2002/00 (2013.01)]

6 Claims

1. A method for reducing symptoms of a disease in an individual in need thereof which method comprises administering to the individual a therapeutically effective amount of a ingestible formulation comprising Citicoline, CoQ10, hydroxyproline, and a niacinamide adenine dinucleotide (NAD+) precursor wherein the disease is a neurological disease.